信得科技SINDER品牌怎么样 申请店铺

我要投票 信得科技SINDER在兽药行业中的票数:518 更新时间:2025-12-14
信得科技SINDER是哪个国家的品牌?「信得科技SINDER」是 山东信得科技股份有限公司 旗下著名品牌。该品牌发源于山东省潍坊市,在1999年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力信得科技SINDER品牌出海!将品牌入驻外推网,定制信得科技SINDER品牌推广信息,可以显著提高信得科技SINDER产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

信得科技SINDER怎么样

山东信得科技股份有限公司,成立于1999年,山东省著名商标,集生物制品/生化制药/兽药制剂/饲料添加剂及兽药原料药的研发、生产和销售于一体的高新技术企业集团


山东信得科技股份有限公司的前身诸城信得药业有限公司成立于1999年4月,公司自成立以来,始终坚持“坚定不移地增加客户价值”的核心理念,实现了持续、健康发展。现已发展成为集研发、生产和销售于一体的企业集团。

目前拥有生物制品、生化制药、兽药制剂、饲料添加剂及兽药原料药五个产品线,集团由山东信得科技股份有限公司,山东信得动物疫苗有限公司、青岛信得药业有限公司、四川华西动物药业有限公司、北京信得威特科技有限公司组成。

集团拥有四个生产基地,其中坐落在诸城开发区的信得生物工业园拥有两个生化制药车间、三个兽药制剂车间、一个原料药合成车间、一个中药提取萃取车间、一个生物酶发酵车间及相应配套设施;北京信得生物制品工厂拥有六条生产线,是国内品种较全的兽用生物制品工厂;山东信得疫苗公司的工厂主要生产高致病性禽流感疫苗;四川华西工厂主要以生产猪药为主,拥有水针、粉针、口服液、中药等多条生产线。

集团拥有两个技术中心,还拥有三个P2实验室、三个国家认证的动物房;P3实验室正在建设之中。

集团研发团队拥有博士、硕士100余名,除了加强自身研发团队建设外,公司联合中国农大、中国农科院、中国兽药监察所、哈兽研、华南农大、青岛农大以及多家兽药企业成立由信得集团担任理事长的中国动物保健产业研发创新联盟,建立了更大的技术创新平台,已经开展的技术合作三十余项;集团还与澳大利亚生物资源公司、法国维克公司、台湾动物疫苗研究所等国际动保公司及研究机构建立了合作关系。

除了在新产品开发上投入很大的资源外,集团还投入巨大的人力物力于动物疫病控制的研究上,集团技术中心设立了猪病和禽病两个实验室,每天对来自全国的病料进行病原分离分析;综合全国的动物疫情设计疾病控制方案,并进行大量的临床试验,以筛选较佳方案;集团还与中国农大赵继勋教授及其研究团队建立了合作关系,跟踪各种传染性疾病的毒株变异,及时改造疫苗毒株。

集团根据服务目标客户设立了八个业务部,实现了技术服务的专业化。八个业务部分别为家禽业务部、家畜业务部、进口疫苗业务部、自产疫苗业务部、国家强制免疫产品业务部、饲料添加剂业务部、原料药业务部、国际业务部。

公司一直把为养殖业提供疾病控制方案作为重要的技术服务支持手段,同时还为合作伙伴提供技术培训、管理咨询等服务支持,帮助合作伙伴做大做强。由于持续的坚持为客户创造价值,信得的品牌得到了养殖业客户的认可。

作为一家富有社会责任感的企业,信得先后为希望工程、抗震救灾等社会公益事业累计捐款、捐物数百万元。


Shandong Xinde Technology Co., Ltd., founded in 1999, is a famous trademark of Shandong Province. Zhucheng Xinde Pharmaceutical Co., Ltd., the predecessor of Shandong Xinde Technology Co., Ltd., was founded in April 1999. Since its establishment, the company has always been Adhering to the core concept of "unswervingly increasing customer value", we have achieved sustained and healthy development. Now it has developed into an enterprise group integrating R & D, production and sales. At present, the group has five product lines of biological products, biochemical pharmaceuticals, veterinary pharmaceutical preparations, feed additives and veterinary drug APIs. The group is composed of Shandong Xinde Technology Co., Ltd., Shandong Xinde animal vaccine Co., Ltd., Qingdao Xinde Pharmaceutical Co., Ltd., Sichuan Huaxi Animal Pharmaceutical Co., Ltd. and Beijing Xinde Weite Technology Co., Ltd. The group has four production bases, including two biochemical pharmaceutical workshops, three veterinary medicine preparation workshops, one API synthesis workshop, one traditional Chinese medicine extraction workshop, one biological enzyme fermentation workshop and corresponding supporting facilities in Xinde bio Industrial Park, which is located in Zhucheng Development Zone; Beijing Xinde bio product factory has six production lines, which are full range of domestic veterinary products Products factory; Shandong Xinde vaccine company's factory mainly produces highly pathogenic avian influenza vaccine; Sichuan Huaxi factory mainly produces swine medicine, with multiple production lines such as water injection, powder injection, oral liquid and traditional Chinese medicine. The group has two technology centers, three P2 laboratories and three national certified animal houses; P3 laboratory is under construction. The R & D team of the group has more than 100 doctors and masters. In addition to strengthening the construction of its own R & D team, the company, together with China Agricultural University, Chinese Academy of Agricultural Sciences, China Veterinary Drug Supervision Institute, Harbin Veterinary Research Institute, South China Agricultural University, Qingdao Agricultural University and a number of veterinary drug enterprises, has established the R & D and innovation alliance of China's animal health industry, with the director of cred group, and established a larger technological innovation platform, More than 30 technical cooperation projects have been carried out; the group has also established cooperation relations with international animal protection companies and research institutions such as Australia biological resources company, France Vick company, Taiwan Animal Vaccine Research Institute, etc. In addition to investing a lot of resources in the development of new products, the group has also invested a lot of manpower and material resources in the research of animal epidemic control. The group technology center has set up two laboratories of pig disease and poultry disease, which carry out pathogen separation and Analysis on disease materials from all over the country every day. The disease control scheme is designed based on the national animal epidemic situation, and a large number of clinical trials are carried out to screen the better prescription The group also established a cooperative relationship with Professor Zhao Jixun and his research team of China Agricultural University to track the strain variation of various infectious diseases and timely modify the vaccine strain. The group has set up eight business departments according to the service target customers, realizing the specialization of technical services. Eight business departments are poultry business department, livestock business department, imported vaccine business department, self produced vaccine business department, national compulsory immunization product business department, feed additive business department, API business department and international business department. The company has always regarded providing disease control programs for the breeding industry as an important technical service support means, and also provided technical training, management consulting and other service support for partners to help them grow bigger and stronger. As a result of continuous adherence to create value for customers, the trusted brand has been recognized by the breeding industry customers. As an enterprise with a sense of social responsibility, trust has donated millions of yuan to hope project, earthquake relief and other social public welfare undertakings.

本文链接: https://brand.waitui.com/10040f1eb.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

应对老年护理刚需,四部门发布《老年护理服务能力提升行动方案》

近日,国家卫生健康委、国家医保局、国家中医药局和国家疾控局四部门发布《老年护理服务能力提升行动方案》(以下简称《行动方案》)提出,到2027年,老年护理资源有效扩容,覆盖机构、社区、居家的老年护理服务体系逐步完善,从业人员服务能力不断提升,老年护理服务持续改善,服务连续性、可及性、规范性持续提高,老年人获得感不断增强。提升老年护理服务能力是深入贯彻实施积极应对人口老龄化国家战略的具体举措。截至2024年底,我国60岁及以上人口数达3.1亿,占总人口的22%,老年人特别是失能老年人对医疗护理服务呈现迫切的刚性需求。(央视新闻)

37分钟前

消息人士称英伟达考虑提高H200芯片产量

消息人士称,英伟达考虑提高H200芯片产量。(新浪财经)

37分钟前

中国造高端工业母机在沈阳下线交付

记者13日从通用技术沈阳机床获悉,由通用技术集团与东方电气集团联合研发的4台高端五轴联动数控机床12日在沈阳下线交付。这一合作在取得重大技术突破的同时,还打破了“研用脱节”的产业困境,开创了国产工业母机研制的新模式。长期以来,国产高端数控机床面临“研发投入大、周期长、验证难”的系统性瓶颈——企业闭门研发与市场实际需求脱节,产品因缺乏真实工况下的长期验证,陷入“用户不愿用、不敢用,技术难迭代、难成熟”的恶性循环,严重制约产业高质量发展。(中新网)

37分钟前

金融时报:将坚持内需主导放在首位

金融时报评论员发布文章称,12月10日至11日,中央经济工作会议在京举行。会议聚焦“当前怎么看”和“明年怎么干”,为中国经济高质量发展把舵定向。站在“十四五”规划收官与“十五五”规划谋篇的历史交汇点,会议强调持续扩大内需、优化供给,将“坚持内需主导,建设强大国内市场”确定为明年经济工作重点任务之首。未来一个时期,我国国内市场主导国民经济循环的特征将更为明显。在内外部发展环境更趋严峻复杂的大背景下,只有坚持立足国内,全方位扩大内需、建设强大国内市场,增强发展主动性,才能够在国际风云变幻中,牢牢把握发展主动权。着眼明年经济社会发展目标任务,做强国内大循环,建设强大国内市场,以国内循环的稳定性对冲国际循环的不确定性,必须坚持内需的主导地位。坚持内需主导,全方位扩大国内需求,要大力提振居民消费。坚持内需主导,全方位扩大国内需求,要推动投资止跌回稳。将坚持内需主导放在首位,是党和国家对当前经济形势的深刻洞察。要全面贯彻明年经济工作的总体要求和政策取向,加快培育完整内需体系,形成消费和投资相互促进的良性循环,将超大规模市场的潜力转化为现实增长动力。

37分钟前

脑虎科技:公司“三全”脑机接口产品成功完成首例临床试验

在今日举行的2025天桥脑科学研究院脑机接口与人工智能论坛中,脑虎科技方面表示,公司自主研发的国内首款、国际第二款内置电池的全植入、全无线、全功能(“三全”)脑机接口产品,在复旦大学附属华山医院毛颖、陈亮教授团队的主持下,成功完成首例临床试验。(财联社)

37分钟前

本页详细列出关于信得科技SINDER的品牌信息,含品牌所属公司介绍,信得科技SINDER所处行业的品牌地位及优势。
咨询